CAR-T cell therapy meets CRISPR. See the results from the first US trial of gene editing in patients with advanced cancer, just published by Carl June and colleagues in Science, together with a perspective by Jennifer Hamilton and Jennifer Doudna and a piece of news by Jennifer Couzin-Frankel. We still don’t know if edited T cells are effective against cancer, but this Phase 1 clinical trial suggests the approach is safe and feasible.
RNA editing takes off. Take a look at the news feature by Sara Reardon in Nature. It’s a four pages introduction to ADAR, an alternative to CRISPR for flexible, reversible therapies.
The year 2019 ended with three years in jail sentenced to He Jiankui for illegal medical practice. The CRISPR-baby scandal’s epilogue was applauded on twitter by a few leading scientists such as Craig Venter and Fyodor Urnov and decried on STAT News by the controversial biohacker Josiah Zayner. Most experts, however, stayed silent.
As stressed by the Washington Post, “the judicial proceedings were not public, and outside experts said it is hard to know what to make of the punishment without the release of the full investigative report or extensive knowledge of Chinese law and the conditions under which He will be incarcerated.”
The picture shows a moment in the sample-collecting effort leading to this Pnas paper about a novel heat-tolerant CRISPR enzyme called IgnaviCas9. Exploring nature’s molecular diversity in extreme environmental conditions such as Yellowstone hot springs can yield exciting discoveries and applications.Continue reading
China is the “Innovation Nation” and “The next biotech superpower”, according to the November issue of Nature Biotechnology. Beijing is “set to challenge the pre-eminence of the US drug market. If it can address gaps in its R&D ecosystem and clinical infrastructure, it may even become a home for biotech innovators”, says the editorial.Continue reading
Great piece of science by the Liu Lab in Nature, describing the brand new “Search-and-replace genome editing without double-strand breaks or donor DNA”. How is the CRISPR community reacting?
Best quote: “One of those ‘Yay, science!!!’ kind of moments” (Fyodor Urnov quoted in Science)
Most ironic: “Congratulations @davidrliu. We’d probably have published this paper as well (The CRISPR Journal tweet)
Best title: Genome Editing Heads to Primetime (Genetic Engineering and Biotechnology News)
Most understated: A New Gene Editing Tool Could Make CRISPR More Precise (Smithsonian Mag)
Most hyped: A New CRISPR Technique Could Fix Almost All Genetic Diseases (Wired)
The ethics of using CRISPR to improve the odds of savior siblings. This is when a couple tries to have another baby who is both healthy and a suitable donor “match” for their older kid (“Could editing the DNA of embryos with CRISPR help save people who are already alive?“, STAT News, Sept. 16).
Carl Zimmer explaining a CRISPR experiment carried out to understand why many cancer drugs fail (“Why Aren’t Cancer Drugs Better? The Targets Might Be Wrong”, New York Times, Sept. 11; see also the paper in Science Translational Medicine)